Sodium cromoglycate in ragweed-allergic conjunctivitis

Greenbaum, Joseph; Cockcroft, Don; Hargreave, Frederick E.; Dolovich, J.

doi:10.1016/0091-6749(77)90006-9

Cited by 32 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For more than 10 years, sodium cromoglycate, in the form of eye-drops (Opticrom®, Fisons pic), has been widely used as an antiallergic agent. Numerous studies have confirmed its efficacy and safety in relieving symptoms of seasonal allergic conjunctivitis (6,8,13), as well as chronic allergic conjunctivitis, e.g., vernal conjunctivitis (7). Sodium cromoglycate is thought to act chiefly through inhibition of mast-cell degranulation (15).…”

mentioning

confidence: 99%

Topical sodium cromoglycate (Opticrom®) relieves ongoing symptoms of allergic conjunctivitis within 2 minutes

Montan

Zetterström

Eliasson³

et al. 1994

Allergy

View full text Add to dashboard Cite

Twelve patients with seasonal allergic conjunctivitis caused by either birch or timothy grass pollen were challenged out of season in both eyes, with the relevant allergen. Itching, redness, swelling, and tearing were assessed on a 0-3 scale. When a positive reaction, i.e., at least 4 points, had occurred in both eyes, one drop of 2% sodium cromoglycate was administered to one eye and one drop of placebo to the other eye in each patient, in a double-blind, randomized fashion. Symptoms were then assessed after 2, 10, 30, and 60 min. Sodium cromoglycate was statistically better than placebo in reducing the symptoms at 2, 10, and 30 min after the treatment had been administered, showing that topical application of 2% sodium cromoglycate can quickly relieve ongoing symptoms of allergic inflammation in the eye.

show abstract

mentioning

confidence: 99%

Topical sodium cromoglycate (Opticrom®) relieves ongoing symptoms of allergic conjunctivitis within 2 minutes

Montan

Zetterström

Eliasson³

et al. 1994

Allergy

View full text Add to dashboard Cite

show abstract

Allergic Conjunctivitis

Owen¹,

Henshaw²,

Smeeth³

et al. 2005

Evidence‐based Ophthalmology

View full text Add to dashboard Cite

Perspectives on the in vitro evaluation of anti‐anaphylactic agents

Weinryb¹,

Coutts²,

Khandwala³

1983

Drug Development Research

View full text Add to dashboard Cite

Weinryb, I., S.M. Coutts, and A.S. Khandwala: Perspectives on the in vitro evaluation of anti-anaphylactic agents. Drug Dev. Res. 3213-219, 1983. In vitro models of anaphylaxis such as the release of mediators from the mast cell can do more than identify compounds with intrinsic anti-allergic activity; they have the potential for development of a detailed profile of activity that may be compared and contrasted in several ways to that of disodium cromoglycate. These parameters include effects upon a) immunologic versus nonimmunologic release, b) IgE-versus IgG-provoked release, c) timing of compound addition relative to challenge, d) repeated administration (presence or absence of tachyphylaxis), e) wash-out of agent (reversibility), and 9 other granulocyte models relative to the mast cell. Use of in vitro models of anaphylaxis in this way allows an early judgment to be made about the extent to which a new compound presents a novel anti-allergic profile.

show abstract

Sodium cromoglycate in ragweed-allergic conjunctivitis

Cited by 32 publications

References 12 publications

Topical sodium cromoglycate (Opticrom®) relieves ongoing symptoms of allergic conjunctivitis within 2 minutes

Topical sodium cromoglycate (Opticrom®) relieves ongoing symptoms of allergic conjunctivitis within 2 minutes

Allergic Conjunctivitis

Perspectives on the in vitro evaluation of anti‐anaphylactic agents

Contact Info

Product

Resources

About